%0 Journal Article
%T Human Herpesvirus 8¨CUnrelated Primary Effusion Lymphoma¨CLike Lymphoma in an Elderly Korean Patient with a Good Response to Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone
%A Jeong-Ok Lee
%A Ji-Young Choe
%A Jong-Seok Lee
%A Junghoon Shin
%A Soo-Mee Bang
%J Archive of "Cancer Research and Treatment : Official Journal of Korean Cancer Association".
%D 2017
%R 10.4143/crt.2016.076
%X Primary effusion lymphoma (PEL) is a rare type of non-Hodgkin¡¯s lymphoma arising from a B-cell lineage characterized by the formation of malignant effusion in body cavities without evidence of a detectable tumor. The effusion contains tumor cells universally infected with human herpesvirus 8 (HHV8), which is the critical factor differentiating PEL from HHV8-unrelated PEL-like lymphoma (PEL-LL). This report describes a 77-year-old male patient with pleural effusion and ascites, containing lymphoma cells expressing a B-cell phenotype, but without markers of HHV8 in immunocytochemical analysis. The patient was diagnosed with PEL-LL and treated with six cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP), which resulted in a complete remission. The patient is currently disease-free 15 months post-treatment. To the best of our knowledge, this is the first report on administration of R-CHOP in a PEL-LL patient in South Korea
%K Primary effusion lymphoma
%K Human herpesvirus 8
%K R-CHOP protocol
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266403/